

Cover Story
Free
Duke University would have avoided embarrassment, a misconduct investigation and a lawsuit, had its top administrators paid closer attention to a thoughtful report by a medical student who saw problems in the lab of the disgraced scientist Anil Potti.
In Brief


Drugs & Targets


Trending Stories
- How George Tidmarsh crossed the FDA-industry Rubicon
- CDER Director Tidmarsh quits amid inspector general probe of his “personal conduct”
Cancer advocates express concern about comments that signal trouble for accelerated approval - Tidmarsh is out, Pazdur is in: FDA’s CDER under new leadership
- Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
- City of Hope’s leadership in lung cancer: Precision, innovation, and a vision for cure
- Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA










